Info

🌱 來自: acute myelogenous leukemia (AML)

consolidation therapy of acute myelogenous leukemia (AML)

If complete remission (CR) =

• ANC >103,
• plt >100,
• no RBC Rx,
• <5% BM blasts; 
• CR ≠ cure

---

• Favorable risk: high-dose cytarabine (HiDAC)
• Intermediate/Poor risk: Allo-HSCT
• Consider maintenance azacitadine if cannot complete curative intent Rx (NEJM 2020;383:2526)

Refractory/relapsed disease

• Repeating mutation analysis b/c clonal evolution common
• FLT3-ITD/TKD mutation: gilteritinib (potent FLT3 inhibitor)
• IDH1 mutation: ivosidenib; 
• IDH2 mutation: enasidenib (small-molecule inhib of IDH1 or 2)

Chemo

• MEC (mitoxantrone, etoposide, Ara-C)
• FLAG-Ida (fludarabine, Ara-C, G-CSF, & idarubicin)
• CLAM (clofarabine, Ara-C, mitoxantrone)
• gemtuzumab